Track topics on Twitter Track topics that are important to you
Elimination Left Atrial Appendage Prevention Thromboembolic Events Patients PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Elimination Left Atrial Appendage Prevention Thromboembolic Events Patients articles that have been published worldwide.
We have published hundreds of Elimination Left Atrial Appendage Prevention Thromboembolic Events Patients news stories on BioPortfolio along with dozens of Elimination Left Atrial Appendage Prevention Thromboembolic Events Patients Clinical Trials and PubMed Articles about Elimination Left Atrial Appendage Prevention Thromboembolic Events Patients for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Elimination Left Atrial Appendage Prevention Thromboembolic Events Patients Companies in our database. You can also find out about relevant Elimination Left Atrial Appendage Prevention Thromboembolic Events Patients Drugs and Medications on this site too.
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the adult population. Thromboembolic events are one of the reson of increased mortality in this group of patients. Oral anticoagulation therapy significantly reduces the risk of complications, however every tenth patient has contraindications to this treatment. Percutaneous left atrial appendage occlusion (LAAO) is effective, non-pharmacological method of treatment through elimination the source of thromi. This procedure is dedicated to patie...
Left atrial appendage thrombi (LAAT) are the main cause of thromboembolic events. Especially, movable type LAAT is high-risk for thromboembolic events. We aimed to investigate the predictors of the movable type LAAT in patients with atrial fibrillation (AF). We retrospectively studied 827 consecutive patients who underwent transthoracic echocardiography (TEE) prior to cardioversion or catheter ablation for AF. Sixty-nine patients who underwent cardiac surgery or significant valvular disease were excluded. T...
Left atrial appendage occluder (LAAO) implantation is an alternative method for stroke prevention in atrial fibrillation (AF) patients who are not eligible for long-term oral anticoagulation. The present paper describes the acute and 1-year follow-up outcome data of the prospective, multicenter German left atrial appendage occlusion registry (LAARGE).
Percutaneous left atrial appendage closure (p-LAAC) emerged as an option for stroke prevention in atrial fibrillation (AF) patients' ineligible for long-term anticoagulation.Real-world data on its in-hospital and 30-day readmission measures are limited.
Congenital absence of left atrial appendage (LAA) is an extremely rare condition and is usually diagnosed incidentally in imaging intended for other purposes. Herein, we report a rare case of absent left atrial appendage in an 80-year-old gentleman who was candidate for radiofrequency catheter ablation procedure for atrial flutter rhythm in whom we observed the absence of left atrial appendage in echocardiographic examination. Computed tomography angiographic examination performed in the evaluation course o...
Percutaneous left atrial appendage closure (LAAC) is an alternative treatment in atrial fibrillation patients with contraindication to oral anticoagulation. Still, patient selection criteria for LAAC are debated.
A significant role of the left atrial appendage (LAA) in the genesis of atrial fibrillation (AF) has been described. LAA electrical isolation (LAAEI) confers substantial long-term clinical benefits. Nevertheless, left phrenic nerve (LPN) is in the vicinity of the LAA and can be injured during radiofrequency ablation at the ostial level.
We present a case report of a 79-year-old woman with permanent atrial fibrillation and Osler-Weber-Rendu disease who underwent percutaneous closure of left atrial appendage. The patient had a history of small bowel resection due to mesenteric embolism and recurrent episodes of gastrointestinal bleeding, epistaxis and hemarthrosis. Bleeding episodes were exacerbated by anticoagulation therapy causing severe anemia that required repeated red blood cells transfusions. Left atrial appendage occlusion with Watch...
Percutaneous Left Atrial Appendage Closure, A Safe Alternative To Anticoagulation For Patients With Non-Valvular Atrial Fibrillation And End-Stage Renal Disease On Hemodialysis: A Single Center Experience.
The evidence about the effectiveness and safety of oral anticoagulation in patients on hemodialysis is conflicting and scarce. Percutaneous left atrial appendage occlusion (LAAO) has demonstrated to be a valid alternative therapeutic option for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). The aim of this study is to present the outcomes of percutaneous LAAO in patients with end-stage renal disease (ESRD) on hemodialysis and NVAF in our center.
Exclusion of electrical and mechanical function of the left atrial appendage in patients with persistent atrial fibrillation: differences in efficacy and safety between endocardial ablation vs epicardial LARIAT ligation (the EXCLUDE LAA study).
Electrical isolation of the left atrial appendage (LAA) may provide incremental benefits for arrhythmia management in patients undergoing radiofrequency ablation (RFA) for persistent atrial fibrillation (AF).
The main purpose of this article is to evaluate an impact of epicardial ligation of the left atrial appendage (LAA) in patients with atrial fibrillation (AF) undergoing off-pump coronary artery bypass grafting (OPCAB) on the development of ischemic stroke and mortality.
Atrial fibrillation (AF) and chronic kidney disease (CKD) are associated with an increased risk of ischemic stroke. The aim of this study was to compare the clinical characteristics, the incidence of left atrial appendage (LAA) thrombus and its predictors, and spontaneous echo contrast (SEC) in a population of patients with AF depending on estimated glomerular filtration rate (eGFR) values.
Peri-device leaks and device thrombi are assumed to lead to ischemic events after percutaneous left atrial appendage occlusion (LAAO). While these device related complications are well assessed until 12 months after LAAO, no data are available beyond this period.
Interventional closure of the left atrial appendage (LAA) is an alternative option to stroke prophylaxis, particularly in multimorbid patients with a high risk of bleeding under oral anticoagulation. Due to the multiple comorbidities, the prognosis of patients is reduced, and the clinical benefit of the procedure is therefore questionable in the individual patient.
Surgical suture or exclusion of the left atrial appendage (LAA) is a commonly performed technique in patients undergoing cardiothoracic revascularization and/or valve repair. However, incomplete surgical sealing of the LAA is not a rare phenomenon and has been shown to strongly increase the risk for future cerebrovascular embolic events. We report the first in man implantation of a Watchman LAA occluder during redo minimally invasive open-heart surgery. This approach offers a new alternative for LAA occlusi...
A 72-year-old man was admitted because of persistent atrial fibrillation after suffering a stroke 4 months prior. A left atrial appendage was discovered and closed using a kissing-Watchman technique.
Atrial fibrillation increases the risk of cerebrovascular events, being responsible of 15-18% of all strokes. The morphological and functional remodelling of the left atrium caused by atrial fibrillation favours blood stasis and, consequently, stroke risk. Several studies suggest that haemodynamic information on the left atrium and the left atrial appendage may help to better characterize stroke risk. The aim of this study was to develop a personalized computational fluid dynamics model of the left atrium w...
The left atrial appendage (LAA) is the most common site of thrombus formation in patients with atrial fibrillation. Therefore, better knowledge of the morphology, physiology, and function of the LAA may provide a better estimate of stroke risk. The LAA morphology is currently classified into 4 categories: chicken-wing (CW), windsock, cauliflower, and cactus. Chicken-wing is the most common and carries lower risk. This classification system, however, lacks consistent inter-rater reliability and correlation w...
To close the left atrial appendage during thoracoscopic ablation of atrial fibrillation, the use of a clipping device has proven to be an elegant and efficacious technique. Although very rare, adequate ostial appendage clipping can provoke coronary artery kinking and thus lead to cardiac ischemia. Here, we describe a minimally invasive surgical technique to deal with this potentially serious complication.
The aim of this study was to asses the feasibility and efficacy of transcatheter leak closure with detachable coils in patients with incomplete left atrial appendage (LAA) closure.
In non-rheumatic atrial fibrillation (AF), left atrial appendage (LAA) is thought to be the source of embolism in 90% of the strokes. Thus, as recent clinical trials have shown the non-inferiority of percutaneous LAA closure (LAAc) in comparison to medical treatment, and despite a IIb recommendation in the latest guidelines for concomitant surgical LAAc, we sought to investigate the beneficial effect of LAAc in the surgical population. A meta-analysis model was performed comparing studies including any card...
A 4-year-old boy presented with intractable atrial tachycardia and heart failure. Antiarrhythmic drugs, such as digoxin, beta-blockers, and amiodarone were ineffective. Although we attempted multiple radiofrequency catheter ablations, the atrial tachycardia arising from left atrial appendage frequently recurred. Finally, we decided to perform atrial appendectomy using the thoracoscopic approach. Immediately after the appendectomy, the atrial tachycardia was terminated and restored to sinus rhythm. Left vent...
Left atrial appendage closure (LAAC) is an alternative to long-term anticoagulation for thromboembolic protection in patients with atrial fibrillation (AF) and high bleeding risk. Short-term Warfarin use following LAAC is well-studied, while data pertaining to novel oral anticoagulant (NOAC) use in this setting is less robust. Specifically, data regarding the safety and efficacy of post-procedural NOAC use in high-risk patients is lacking.